Affymetrix Acquires Assets of Eureka Genomics Corporation to Provide High Throughput and Economical Crop and Animal Genotyping
May 14 2015 - 5:00AM
Business Wire
Affymetrix, Inc., (NASDAQ:AFFX) announced today that it has
acquired substantially all the assets of Hercules, CA-based Eureka
Genomics® Corporation for $15 million in an all cash transaction.
Eureka Genomics is a developer of cost-effective, low- to mid-plex,
high throughput genotyping assays that use common next-generation
sequencing (NGS) platforms for signal readout. These assays enable
the detection of hundreds to thousands of genetic markers which are
increasingly in demand for routine crop and animal agrigenomics
testing.
Affymetrix will immediately launch the Eureka Genomics’
technologies as Eureka Genotyping Solution and Services for use in
a wide range of routine animal and plant testing applications
through an early access program.
“Our array-based Axiom genotyping platform has achieved great
commercial success in agrigenomics markets. An emerging segment of
our customers have been asking for a cost-effective solution with
focused genetic variant panels for very high volume routine testing
in animal and plant applications such as parentage, traceability or
trait management,” said Frank Witney, President and Chief Executive
Officer of Affymetrix. “This acquisition will extend the continuum
of our product offerings enabling us to support more applications
for our current customers and to serve new customers.”
Eureka Genomics has been collaborating with and providing NGS,
genomics, genotyping, and bioinformatics services to government
agencies, universities, research centers, and agrigenomic companies
since 2008. “We are very pleased that Eureka Genomics products and
service technologies will become part of the Affymetrix portfolio,”
stated Didier Perez, Chief Operating Officer of Eureka Genomics.
“By leveraging Affymetrix infrastructure and commercial reach, the
advanced technologies Eureka Genomics developed will now be
accessed by more customers on a global scale.”
Concurrent with the acquisition, Affymetrix entered into a new
multi-year partnership agreement to provide the Eureka Genomics
technologies to the animal genetics business of Zoetis Inc.
Affymetrix will grant Zoetis certain preferred rights to
incorporate the Eureka Genomics technologies in its cattle and
sheep genomic products. “We are delighted about the opportunity to
work closely with a market leader in animal health, helping Zoetis
bring this leading genotyping technology to their customers
globally,” said Laurent Bellon, Ph.D., SVP and General Manager,
Genetic Analysis Business Unit – Genotyping, at Affymetrix. “Our
newly acquired Eureka Genomics technologies are uniquely suited to
high-volume marker-assisted management applications.”
PLEASE NOTE: Affymetrix, the Affymetrix logo,
Axiom, and Eureka Genomics trademarks are the property
of Affymetrix, Inc. All other trademarks are the property
of their respective owners.
About Affymetrix
Affymetrix technologies enable multiplex and simultaneous
analysis of biological systems at the cell, protein, and gene
level, facilitating the rapid translation of bench-top research
into clinical and routine use for human health and wellness. The
Company provides leadership and support, partnering with customers
in pharmaceutical, diagnostic, and biotechnology companies, as well
as leading academic, government, and non-profit research institutes
in their quest to use biology for a better world. More than 2,300
microarray systems have been shipped around the world and more than
94,000 peer-reviewed papers have been published citing Affymetrix
technologies. Affymetrix is headquartered in Santa Clara,
California, and has manufacturing facilities in Cleveland, Ohio,
San Diego, Vienna, and Singapore. The Company has about 1,100
employees worldwide and maintains sales and distribution operations
across Europe, Asia, and Latin America. For more information about
Affymetrix, please visit www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix' "expectations," "beliefs," "hopes,"
"intentions," "strategies," or the like. Such statements are
subject to risks and uncertainties that could cause actual results
to differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the
year ended December 31, 2014, and other SEC reports for subsequent
quarterly periods.
Affymetrix Contacts:Media Contact:Mindy Lee-Olsen,
408-731-5523Vice President, Marketing
Servicesmindy_lee-olsen@affymetrix.comorInvestor Contact:Doug
Farrell, 408-731-5285Vice President, Investor
Relationsdoug_farrell@affymetrix.com
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2023 to Jul 2024